Human IgG1 (K214R) kappa-Deruxtecan, ADC Control (DAR 4) is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with an average DAR of 4. It can be used as a control in ADC.
Human IgG1 kappa-Deruxtecan, ADC Control (DAR 4) is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with an average DAR of 4. It can be used as a control in ADC.
Human IgG1 (K214R) kappa-Deruxtecan, ADC Control (DAR 8) is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with an average DAR of 8. It can be used as a control in ADC.
Human IgG1 kappa-Deruxtecan, ADC Control (DAR 8) is an IgG1-based antibody-drug conjugate control containing Deruxtecan (DXd) with an average DAR of 8. It can be used as a control in ADC.
Dihydrexidine is a full efficacy D1-like dopamine receptor (D1/D5) agonist (IC50: 10 nM for D1 receptor). It also shows potent antiparkinsonian activity.